Title
Category
Credits
Event date
Cost
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in Acne Vulgaris presented at the 28th Annual Masters of Pediatric Dermatology and the 18th Annual South Beach Symposium:Acne Diagnosis and Treatment in WomenTherapeutic Advancements in Acne & Rosacea TherapyLatest Developments in Lasers and Light Therapies for AcneControversies in Oral Therapy for AcnePediatric Perspective: Video and slide highlights will also be included from the Masters of Pediatric Dermatology conference for learners interested in the pediatric perspective.
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in Atopic Dermatitis (AD) presented at the 28th Masters of Pediatric Dermatology and the 18th Annual South Beach Symposium from high caliber Dermatology physicians below:
  • LivDerm
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Atopic dermatitis is a complex immune disease that has several distinct manifestations across age groups. Published evidence has shown that significant gaps exist in the management of AD, including an under-diagnosis of both children and adults and an incomplete evidence-base for the use of traditional AD therapies across pediatric patients. In addition, most patients and clinicians are not satisfied with current treatments for AD.
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The ever-increasing presence of a variety of dermatologic conditions across the lifespan, including in neonates, children, and adolescents continues to be a major challenge for healthcare providers in the United States.  Current estimates predict that up to 30% of primary care visits in the US involve a skin-related issue, with some of the most common conditions including atopic dermatitis, seborrheic dermatitis, contact dermatitis, acne, neonatal rashes, and sunburn among others (Castelo-Soccio 2017).  There is a shortage of pediatric dermatologists in the United States, and more often the
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD and PAD compared to patients with these conditions and no concomitant diabetes. As such, current antithrombotic strategies to prevent adverse events in these high-risk patients may not be adequate, and several recently-completed and ongoing clinical trials are evaluating the efficacy and safety of additional approaches, including the use of more aggressive and specific antithrombotic agents in this setting.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Lowering LDL-C effectively and safely is crucial in preventing ASCVD events. Even with the advances in LDL-C-lowering therapy, there is considerable residual risk due to suboptimal adherence, clinical efficacy, or clinical inertia, which increases the chances of serious adverse CV events. Several new and emerging agents may help address these gaps in the near future, and clinicians need to be aware of these new approaches and their potential role in the treatment of high-risk patients with elevated LDL-C.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Despite advances in understanding, prevention, and treatment, influenza is still associated with a constant public health concern. Moreover, in patients with chronic conditions, including those with diabetes, cardiovascular disease, renal impairment, or with cardiometabolic risk factors (obesity, tobacco users), influenza can often lead to severe or even fatal disease.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Chronic obstructive pulmonary disease (COPD) is a chronic, complex disease with multiple systemic effects, including cardiometabolic conditions, which not only influence patient adherence by adding to the burden of pharmacotherapy, but may also impact COPD therapeutic decisions.
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Patient with ILDs, especially those with a progressive fibrosis phenotype, maybe at a greater risk for having worse outcomes with COVID-19, including during and post-COVID-19 infection. However, the management of patients with PF-ILDs and COVID-19 is not clear, including the potential management of COVID-19 related lung injury and fibrosis, as well as the overall management of ILDs in the COVID-19 era. During this webcast, experts will discuss these gaps and the implications of COVID-19 in the management of patients with ILDs and PF-ILD.

Pages